Benitec announced this week that it has formed a collaboration with the Children's Cancer Institute Australia for Medical Research to develop an RNAi-based therapeutic for lung cancer.

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi. A CCIA researcher and Benitec collaborator has previously demonstrated that beta III-tubulin inhibition using an expressed RNAi approach can sensitize tumors to various chemotherapeutics, it added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.